277 related articles for article (PubMed ID: 29153840)
1. Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma.
Yu KH; Berry GJ; Rubin DL; Ré C; Altman RB; Snyder M
Cell Syst; 2017 Dec; 5(6):620-627.e3. PubMed ID: 29153840
[TBL] [Abstract][Full Text] [Related]
2. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features.
Yu KH; Zhang C; Berry GJ; Altman RB; Ré C; Rubin DL; Snyder M
Nat Commun; 2016 Aug; 7():12474. PubMed ID: 27527408
[TBL] [Abstract][Full Text] [Related]
3. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
4. Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks.
Yu KH; Wang F; Berry GJ; Ré C; Altman RB; Snyder M; Kohane IS
J Am Med Inform Assoc; 2020 May; 27(5):757-769. PubMed ID: 32364237
[TBL] [Abstract][Full Text] [Related]
5. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
6. Integrated quantitative proteomic and transcriptomic analysis of lung tumor and control tissue: a lung cancer showcase.
Tenzer S; Leidinger P; Backes C; Huwer H; Hildebrandt A; Lenhof HP; Wesse T; Franke A; Meese E; Keller A
Oncotarget; 2016 Mar; 7(12):14857-70. PubMed ID: 26930711
[TBL] [Abstract][Full Text] [Related]
7. Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Zeng H; Chen L; Zhang M; Luo Y; Ma X
Gynecol Oncol; 2021 Oct; 163(1):171-180. PubMed ID: 34275655
[TBL] [Abstract][Full Text] [Related]
8. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression differentiates histology and predicts survival of lung cancer.
Landi MT; Zhao Y; Rotunno M; Koshiol J; Liu H; Bergen AW; Rubagotti M; Goldstein AM; Linnoila I; Marincola FM; Tucker MA; Bertazzi PA; Pesatori AC; Caporaso NE; McShane LM; Wang E
Clin Cancer Res; 2010 Jan; 16(2):430-41. PubMed ID: 20068076
[TBL] [Abstract][Full Text] [Related]
10. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.
Wan YW; Sabbagh E; Raese R; Qian Y; Luo D; Denvir J; Vallyathan V; Castranova V; Guo NL
PLoS One; 2010 Aug; 5(8):e12222. PubMed ID: 20808922
[TBL] [Abstract][Full Text] [Related]
11. A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
Jones GD; Brandt WS; Shen R; Sanchez-Vega F; Tan KS; Martin A; Zhou J; Berger M; Solit DB; Schultz N; Rizvi H; Liu Y; Adamski A; Chaft JE; Riely GJ; Rocco G; Bott MJ; Molena D; Ladanyi M; Travis WD; Rekhtman N; Park BJ; Adusumilli PS; Lyden D; Imielinski M; Mayo MW; Li BT; Jones DR
JAMA Surg; 2021 Feb; 156(2):e205601. PubMed ID: 33355651
[TBL] [Abstract][Full Text] [Related]
12. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
14. Multi-omics facilitated variable selection in Cox-regression model for cancer prognosis prediction.
Liu C; Wang X; Genchev GZ; Lu H
Methods; 2017 Jul; 124():100-107. PubMed ID: 28627406
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
16. WDR62 overexpression is associated with a poor prognosis in patients with lung adenocarcinoma.
Shinmura K; Kato H; Kawanishi Y; Igarashi H; Inoue Y; Yoshimura K; Nakamura S; Fujita H; Funai K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
Mol Carcinog; 2017 Aug; 56(8):1984-1991. PubMed ID: 28277612
[TBL] [Abstract][Full Text] [Related]
17. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images.
Sadhwani A; Chang HW; Behrooz A; Brown T; Auvigne-Flament I; Patel H; Findlater R; Velez V; Tan F; Tekiela K; Wulczyn E; Yi ES; Mermel CH; Hanks D; Chen PC; Kulig K; Batenchuk C; Steiner DF; Cimermancic P
Sci Rep; 2021 Aug; 11(1):16605. PubMed ID: 34400666
[TBL] [Abstract][Full Text] [Related]
19. Integrative Proteomic Characterization of Human Lung Adenocarcinoma.
Xu JY; Zhang C; Wang X; Zhai L; Ma Y; Mao Y; Qian K; Sun C; Liu Z; Jiang S; Wang M; Feng L; Zhao L; Liu P; Wang B; Zhao X; Xie H; Yang X; Zhao L; Chang Y; Jia J; Wang X; Zhang Y; Wang Y; Yang Y; Wu Z; Yang L; Liu B; Zhao T; Ren S; Sun A; Zhao Y; Ying W; Wang F; Wang G; Zhang Y; Cheng S; Qin J; Qian X; Wang Y; Li J; He F; Xiao T; Tan M
Cell; 2020 Jul; 182(1):245-261.e17. PubMed ID: 32649877
[TBL] [Abstract][Full Text] [Related]
20. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
